Navigation Links
Chiltern Announces Collaboration With Dr Nawab Qizilbash

LONDON, Dec. 17 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, is pleased to announce our collaboration with Dr Nawab Qizilbash of OXON Epidemiology.

Dr Nawab Qizilbash, MBChB BSc MRCP (UK) MSc Phil (Oxon) is the Director of OXON Epidemiology Ltd. He served as Director of Epidemiology and Evidence-based Medicine at GlaxoSmithKline. Formerly an Honorary Consultant Physician/Senior Research Fellow at Radcliffe Infirmary, Oxford University, Nawab trained under Professor Sir Richard Peto F.R.S. in epidemiology, Phase IV trials and meta-analysis. He also collaborates with Professor Stephen Evans in academic research on statistical signal detection. Dr Qizilbash has authored 5 publications in the Lancet, 1 in the Journal of the American Medical Association and 1 in the British Medical Journal, among others. He founded the Cochrane Dementia Group and is chief editor of an international textbook on clinical dementia.

Jane Turner, MRPharmS, Chiltern's Late Phase Director, Europe, stated, "We are delighted to announce the alliance between Chiltern Late Phase and Dr Nawab Qizilbash and his company, OXON Epidemiology Ltd. OXON is a niche consultancy company that specializes in 'real world data': epidemiology, risk management and health economics. This partnership will allow Chiltern to provide epidemiology and outcomes research expertise in conjunction with flexible and bespoke late phase study solutions to our sponsors. Steve Albrecht, Global head of Chiltern Late Phase, added, "We are excited about this ongoing collaboration which significantly strengthens Chiltern's global service offering in epidemiology, pharmacoeconomics and risk management.

Dr Qizilbash commented, "OXON is delighted to be collaborating with Chiltern Late Phase. The combination provides scientific strength with breadth and global reach to late phase, allowing for strategic consulting, planning and implementation of: observational studies, risk management, health economics and Phase IV trials."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 29 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information:

    For More Information:

    Natalie Chong, Chiltern International Ltd.
    171 Bath Road
    Slough, Berkshire SL1 4AA, UK
    Tel:  44 (0) 1753 512 000

    Sue Ojanen, Chiltern International Inc.
    1241 Volunteer Parkway
    Bristol, TN 37620, USA
    Tel:  1 (423) 968 9533

SOURCE Chiltern

SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: